Thursday, June 26, 2025 6/26/2025

GUANIDINIUM DERIVATIVES FOR THE TREATMENT OF OCULAR PAIN

Award Number: R44EY025921
ORGANIZATION: NATIONAL EYE INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/01/2015
PERIOD OF PERFORMANCE END DATE: 06/30/2021

Group Awards By:

View Award Description

GUANIDINIUM DERIVATIVES FOR THE TREATMENT OF OCULAR PAIN - PROJECT SUMMARY The absence of safe and effective strategies for the management of ocular pain is motivating the development of a novel topical drug suitable for patient self-administration. Conventional local anesthetics, such as proparacaine, inhibit voltage-gated Na+ ion channels (NaV) and are highly effective for the management of ocular pain in acute, in-office settings. However, these agents are short acting and toxic to the corneal surface, which prevents their use beyond a few administrations. SiteOne Therapeutics has discovered a chemical series of novel, exquisitely selective inhibitors of human NaV1.7, a subtype implicated in the transmission of pain signals by human genetics. These compounds exhibit excellent analgesic effects when administered systemically. Topical ocular administration is well tolerated and leads to good intraocular exposure. The goal of this phase II grant is to fund preclinical studies including candidate selection, formulation development, and early IND-enabling studies.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2019	SITEONE THERAPEUTICS, INC.	280 UTAH AVE	SOUTH SAN FRANCISCO	CA	94080	SAN MATEO	USA	Vision Research	000	3	10/13/2021	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2020 ( Subtotal = $0 )
2020	2019	SITEONE THERAPEUTICS, INC.	351 EVERGREEN DR STE B-1	BOZEMAN	MT	59715	GALLATIN	USA	Vision Research	000	3	3/12/2020	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2019 ( Subtotal = $888,892 )
2019	2019	SITEONE THERAPEUTICS, INC.	203 ENTERPRISE BLVD STE 3	BOZEMAN	MT	59718	GALLATIN	USA	Vision Research	001	3	8/13/2019	NON-COMPETING CONTINUATION	$888,892
2019	2018	SITEONE THERAPEUTICS, INC.	203 ENTERPRISE BLVD STE 3	BOZEMAN	MT	59718	GALLATIN	USA	Vision Research	000	2	11/30/2018	COMPETING CONTINUATION	$0
														Subtotal = $888,892

Issue Date FY: 2018 ( Subtotal = $601,128 )
2018	2018	SITEONE THERAPEUTICS, INC.	203 ENTERPRISE BLVD STE 3	BOZEMAN	MT	59718	GALLATIN	USA	Vision Research	000	2	9/20/2018	COMPETING CONTINUATION	$601,128
														Subtotal = $601,128

Grand Total All Awards = $1,490,020

Top

All Categories

About

Search

Reports

Data Submission

Award Information

GUANIDINIUM DERIVATIVES FOR THE TREATMENT OF OCULAR PAIN

Award Number: R44EY025921

ORGANIZATION: NATIONAL EYE INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/01/2015

PERIOD OF PERFORMANCE END DATE: 06/30/2021

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer